Pharmacogenomic alerts: Developing guidance for use by healthcare professionals

Aims For diseases with a genetic cause, genomics can deliver improved diagnostics and facilitate access to targeted treatments. Drug pharmacodynamics and pharmacokinetics are often dependent on genetic variation underlying these processes. As pharmacogenomics comes of age, it may be the first way in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of clinical pharmacology 2022-07, Vol.88 (7), p.3201-3210
Hauptverfasser: Carter, John‐Paul L., Critchlow, James, Jackson, Sarah, Sanghvi, Sonali, Feger, Helene, Chaudhry, Afzal, Foley, Lorraine, Sofat, Reecha
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3210
container_issue 7
container_start_page 3201
container_title British journal of clinical pharmacology
container_volume 88
creator Carter, John‐Paul L.
Critchlow, James
Jackson, Sarah
Sanghvi, Sonali
Feger, Helene
Chaudhry, Afzal
Foley, Lorraine
Sofat, Reecha
description Aims For diseases with a genetic cause, genomics can deliver improved diagnostics and facilitate access to targeted treatments. Drug pharmacodynamics and pharmacokinetics are often dependent on genetic variation underlying these processes. As pharmacogenomics comes of age, it may be the first way in which genomics is utilised at a population level. Still required is guidance and standards of how genomic information can be communicated within the health record, and how clinicians should be alerted to variation impacting the use of medicines. Methods The Professional Record Standards Body commissioned by NHS England developed guidance on using pharmacogenomics information in clinical practice. We conducted research with those implementing pharmacogenomics in England and internationally to produce guidance and recommendations for a systems‐based approach. Results A consensus viewpoint is that systems need to be in place to ensure the safe provision of pharmacogenomics information that is curated, actionable and up‐to‐date. Standards should be established with respect to notification and information exchange, which could impact new or existing prescribing and these must be in keeping with routine practice. Alerting systems should contribute to safer practices. Conclusion Ensuring pharmacogenetics information is available to make safer use of medicines will require a major effort, of which this guidance is a beginning. Standards are required to ensure useful genomic information within the health record can be communicated to clinicians in the right format and at the right times to be actioned successfully. A multidisciplinary group of stakeholders must be engaged in developing pharmacogenomic standards to support the most appropriate prescribing.
doi_str_mv 10.1111/bcp.15234
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9305234</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2622276032</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4154-b3bfcb980dc2fdd7ba56d323301f7ae0812a4fadbfc2fba0b609b742aa2ab94e3</originalsourceid><addsrcrecordid>eNp1kT1v2zAQhomiQeO4HfoHCo3toIQfIm1lKJA6XwUC2EMyE0fqaLOQRJWUEvjfR4EdIxlyyw334LnDvYR8Z_SUjXVmbHfKJBfFJzJhQsmcMy4_kwkVVOWSS3ZMTlL6RykTTMkv5FhIqihT5YQsVxuIDdiwxjY03mZQY-zTeXaJj1iHzrfrbD34ClqLmQsxGxJmZpttEOp-YyFi1sXgMCUfWqjTV3Lkxobf9n1KHq6v7he3-d3y5u_i4i63BZNFboRx1pRzWlnuqmpmQKpKcCEoczNAOmccCgfVSHFngBpFSzMrOAAHUxYopuT3ztsNpsHKYttHqHUXfQNxqwN4_X7S-o1eh0ddCvryqVHwcy-I4f-AqdeNTxbrGloMQ9Jccc5nio5HTcmvHWpjSCmiO6xhVL8EoMcANNtrf7y960C-fnwEznbAk69x-7FJ_1msdspnAzqSfQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2622276032</pqid></control><display><type>article</type><title>Pharmacogenomic alerts: Developing guidance for use by healthcare professionals</title><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Free Content</source><creator>Carter, John‐Paul L. ; Critchlow, James ; Jackson, Sarah ; Sanghvi, Sonali ; Feger, Helene ; Chaudhry, Afzal ; Foley, Lorraine ; Sofat, Reecha</creator><creatorcontrib>Carter, John‐Paul L. ; Critchlow, James ; Jackson, Sarah ; Sanghvi, Sonali ; Feger, Helene ; Chaudhry, Afzal ; Foley, Lorraine ; Sofat, Reecha</creatorcontrib><description>Aims For diseases with a genetic cause, genomics can deliver improved diagnostics and facilitate access to targeted treatments. Drug pharmacodynamics and pharmacokinetics are often dependent on genetic variation underlying these processes. As pharmacogenomics comes of age, it may be the first way in which genomics is utilised at a population level. Still required is guidance and standards of how genomic information can be communicated within the health record, and how clinicians should be alerted to variation impacting the use of medicines. Methods The Professional Record Standards Body commissioned by NHS England developed guidance on using pharmacogenomics information in clinical practice. We conducted research with those implementing pharmacogenomics in England and internationally to produce guidance and recommendations for a systems‐based approach. Results A consensus viewpoint is that systems need to be in place to ensure the safe provision of pharmacogenomics information that is curated, actionable and up‐to‐date. Standards should be established with respect to notification and information exchange, which could impact new or existing prescribing and these must be in keeping with routine practice. Alerting systems should contribute to safer practices. Conclusion Ensuring pharmacogenetics information is available to make safer use of medicines will require a major effort, of which this guidance is a beginning. Standards are required to ensure useful genomic information within the health record can be communicated to clinicians in the right format and at the right times to be actioned successfully. A multidisciplinary group of stakeholders must be engaged in developing pharmacogenomic standards to support the most appropriate prescribing.</description><identifier>ISSN: 0306-5251</identifier><identifier>EISSN: 1365-2125</identifier><identifier>DOI: 10.1111/bcp.15234</identifier><identifier>PMID: 35060169</identifier><language>eng</language><publisher>England: John Wiley and Sons Inc</publisher><subject>alerts ; electronic health records ; genomics ; Original ; pharmacogenomics</subject><ispartof>British journal of clinical pharmacology, 2022-07, Vol.88 (7), p.3201-3210</ispartof><rights>2022 The Authors. published by John Wiley &amp; Sons Ltd on behalf of British Pharmacological Society.</rights><rights>2022 The Authors. British Journal of Clinical Pharmacology published by John Wiley &amp; Sons Ltd on behalf of British Pharmacological Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4154-b3bfcb980dc2fdd7ba56d323301f7ae0812a4fadbfc2fba0b609b742aa2ab94e3</citedby><cites>FETCH-LOGICAL-c4154-b3bfcb980dc2fdd7ba56d323301f7ae0812a4fadbfc2fba0b609b742aa2ab94e3</cites><orcidid>0000-0002-0242-6115 ; 0000-0002-1937-5430 ; 0000-0002-2284-3362</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbcp.15234$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbcp.15234$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,777,781,882,1412,1428,27905,27906,45555,45556,46390,46814</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35060169$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carter, John‐Paul L.</creatorcontrib><creatorcontrib>Critchlow, James</creatorcontrib><creatorcontrib>Jackson, Sarah</creatorcontrib><creatorcontrib>Sanghvi, Sonali</creatorcontrib><creatorcontrib>Feger, Helene</creatorcontrib><creatorcontrib>Chaudhry, Afzal</creatorcontrib><creatorcontrib>Foley, Lorraine</creatorcontrib><creatorcontrib>Sofat, Reecha</creatorcontrib><title>Pharmacogenomic alerts: Developing guidance for use by healthcare professionals</title><title>British journal of clinical pharmacology</title><addtitle>Br J Clin Pharmacol</addtitle><description>Aims For diseases with a genetic cause, genomics can deliver improved diagnostics and facilitate access to targeted treatments. Drug pharmacodynamics and pharmacokinetics are often dependent on genetic variation underlying these processes. As pharmacogenomics comes of age, it may be the first way in which genomics is utilised at a population level. Still required is guidance and standards of how genomic information can be communicated within the health record, and how clinicians should be alerted to variation impacting the use of medicines. Methods The Professional Record Standards Body commissioned by NHS England developed guidance on using pharmacogenomics information in clinical practice. We conducted research with those implementing pharmacogenomics in England and internationally to produce guidance and recommendations for a systems‐based approach. Results A consensus viewpoint is that systems need to be in place to ensure the safe provision of pharmacogenomics information that is curated, actionable and up‐to‐date. Standards should be established with respect to notification and information exchange, which could impact new or existing prescribing and these must be in keeping with routine practice. Alerting systems should contribute to safer practices. Conclusion Ensuring pharmacogenetics information is available to make safer use of medicines will require a major effort, of which this guidance is a beginning. Standards are required to ensure useful genomic information within the health record can be communicated to clinicians in the right format and at the right times to be actioned successfully. A multidisciplinary group of stakeholders must be engaged in developing pharmacogenomic standards to support the most appropriate prescribing.</description><subject>alerts</subject><subject>electronic health records</subject><subject>genomics</subject><subject>Original</subject><subject>pharmacogenomics</subject><issn>0306-5251</issn><issn>1365-2125</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><recordid>eNp1kT1v2zAQhomiQeO4HfoHCo3toIQfIm1lKJA6XwUC2EMyE0fqaLOQRJWUEvjfR4EdIxlyyw334LnDvYR8Z_SUjXVmbHfKJBfFJzJhQsmcMy4_kwkVVOWSS3ZMTlL6RykTTMkv5FhIqihT5YQsVxuIDdiwxjY03mZQY-zTeXaJj1iHzrfrbD34ClqLmQsxGxJmZpttEOp-YyFi1sXgMCUfWqjTV3Lkxobf9n1KHq6v7he3-d3y5u_i4i63BZNFboRx1pRzWlnuqmpmQKpKcCEoczNAOmccCgfVSHFngBpFSzMrOAAHUxYopuT3ztsNpsHKYttHqHUXfQNxqwN4_X7S-o1eh0ddCvryqVHwcy-I4f-AqdeNTxbrGloMQ9Jccc5nio5HTcmvHWpjSCmiO6xhVL8EoMcANNtrf7y960C-fnwEznbAk69x-7FJ_1msdspnAzqSfQ</recordid><startdate>202207</startdate><enddate>202207</enddate><creator>Carter, John‐Paul L.</creator><creator>Critchlow, James</creator><creator>Jackson, Sarah</creator><creator>Sanghvi, Sonali</creator><creator>Feger, Helene</creator><creator>Chaudhry, Afzal</creator><creator>Foley, Lorraine</creator><creator>Sofat, Reecha</creator><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0242-6115</orcidid><orcidid>https://orcid.org/0000-0002-1937-5430</orcidid><orcidid>https://orcid.org/0000-0002-2284-3362</orcidid></search><sort><creationdate>202207</creationdate><title>Pharmacogenomic alerts: Developing guidance for use by healthcare professionals</title><author>Carter, John‐Paul L. ; Critchlow, James ; Jackson, Sarah ; Sanghvi, Sonali ; Feger, Helene ; Chaudhry, Afzal ; Foley, Lorraine ; Sofat, Reecha</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4154-b3bfcb980dc2fdd7ba56d323301f7ae0812a4fadbfc2fba0b609b742aa2ab94e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>alerts</topic><topic>electronic health records</topic><topic>genomics</topic><topic>Original</topic><topic>pharmacogenomics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carter, John‐Paul L.</creatorcontrib><creatorcontrib>Critchlow, James</creatorcontrib><creatorcontrib>Jackson, Sarah</creatorcontrib><creatorcontrib>Sanghvi, Sonali</creatorcontrib><creatorcontrib>Feger, Helene</creatorcontrib><creatorcontrib>Chaudhry, Afzal</creatorcontrib><creatorcontrib>Foley, Lorraine</creatorcontrib><creatorcontrib>Sofat, Reecha</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Free Content</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carter, John‐Paul L.</au><au>Critchlow, James</au><au>Jackson, Sarah</au><au>Sanghvi, Sonali</au><au>Feger, Helene</au><au>Chaudhry, Afzal</au><au>Foley, Lorraine</au><au>Sofat, Reecha</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacogenomic alerts: Developing guidance for use by healthcare professionals</atitle><jtitle>British journal of clinical pharmacology</jtitle><addtitle>Br J Clin Pharmacol</addtitle><date>2022-07</date><risdate>2022</risdate><volume>88</volume><issue>7</issue><spage>3201</spage><epage>3210</epage><pages>3201-3210</pages><issn>0306-5251</issn><eissn>1365-2125</eissn><abstract>Aims For diseases with a genetic cause, genomics can deliver improved diagnostics and facilitate access to targeted treatments. Drug pharmacodynamics and pharmacokinetics are often dependent on genetic variation underlying these processes. As pharmacogenomics comes of age, it may be the first way in which genomics is utilised at a population level. Still required is guidance and standards of how genomic information can be communicated within the health record, and how clinicians should be alerted to variation impacting the use of medicines. Methods The Professional Record Standards Body commissioned by NHS England developed guidance on using pharmacogenomics information in clinical practice. We conducted research with those implementing pharmacogenomics in England and internationally to produce guidance and recommendations for a systems‐based approach. Results A consensus viewpoint is that systems need to be in place to ensure the safe provision of pharmacogenomics information that is curated, actionable and up‐to‐date. Standards should be established with respect to notification and information exchange, which could impact new or existing prescribing and these must be in keeping with routine practice. Alerting systems should contribute to safer practices. Conclusion Ensuring pharmacogenetics information is available to make safer use of medicines will require a major effort, of which this guidance is a beginning. Standards are required to ensure useful genomic information within the health record can be communicated to clinicians in the right format and at the right times to be actioned successfully. A multidisciplinary group of stakeholders must be engaged in developing pharmacogenomic standards to support the most appropriate prescribing.</abstract><cop>England</cop><pub>John Wiley and Sons Inc</pub><pmid>35060169</pmid><doi>10.1111/bcp.15234</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-0242-6115</orcidid><orcidid>https://orcid.org/0000-0002-1937-5430</orcidid><orcidid>https://orcid.org/0000-0002-2284-3362</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0306-5251
ispartof British journal of clinical pharmacology, 2022-07, Vol.88 (7), p.3201-3210
issn 0306-5251
1365-2125
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9305234
source Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Free Content
subjects alerts
electronic health records
genomics
Original
pharmacogenomics
title Pharmacogenomic alerts: Developing guidance for use by healthcare professionals
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T11%3A32%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacogenomic%20alerts:%20Developing%20guidance%20for%20use%20by%20healthcare%20professionals&rft.jtitle=British%20journal%20of%20clinical%20pharmacology&rft.au=Carter,%20John%E2%80%90Paul%20L.&rft.date=2022-07&rft.volume=88&rft.issue=7&rft.spage=3201&rft.epage=3210&rft.pages=3201-3210&rft.issn=0306-5251&rft.eissn=1365-2125&rft_id=info:doi/10.1111/bcp.15234&rft_dat=%3Cproquest_pubme%3E2622276032%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2622276032&rft_id=info:pmid/35060169&rfr_iscdi=true